Clinical Trial Update: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing alternative ranibizumab dosages for safety and efficacy in treating retinopathy of prematurity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: University Hospital Freiburg | Conditions: Retinopathy of Prematurity (ROP) | Phase 2 | Status: COMPLETED